'Cholera - Pipeline Review, H2 2016'; Cholera pipeline therapeutics constitutes close to 11 molecules. Out of which approximately 3 molecules are developed by Companies and remaining by the Universities
Furthermore, the publisher says; Cholera is an acute infectious disease caused by a bacterium, Vibrio cholera, which results in a painless, watery diarrhea in humans. Symptoms of cholera can begin as soon as a few hours or as long as five days after infection. Often symptoms are mild. But sometimes they are very serious. Signs and symptoms of Cholera include rapid heart rate, loss of skin elasticity, low blood pressure, thirst, muscle cramps. If not treated, this can lead to shock and death in a matter of hours.
The report 'Cholera - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Cholera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews of key players involved in therapeutic development for Cholera and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III and Phase I stages are 1 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 1 molecules, respectively.
Key Topics Covered:
- Cholera Overview
- Therapeutics Development
- Pipeline Products for Cholera - Overview
- Pipeline Products for Cholera - Comparative Analysis
- Cholera - Therapeutics under Development by Companies
- Cholera - Therapeutics under Investigation by Universities/Institutes
- Cholera Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Cholera - Products under Development by Companies
- Cholera - Products under Investigation by Universities/Institutes
- Cholera - Companies Involved in Therapeutics Development
- Beijing Minhai Biotechnology Co., Ltd
- MSD Wellcome Trust Hilleman Laboratories, Pvt. Ltd.
For more information about this report visit http://www.researchandmarkets.com/research/585k53/cholera